2,873
Participants
Start Date
March 15, 2010
Primary Completion Date
May 26, 2019
Study Completion Date
May 26, 2019
Target : 100 mg/dL (+/-10 mg/dL)
Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
70 mg/dL
Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
BICHAT HOSPITAL Departement of Neurology, Paris
BICHAT HOSPITAL Department of neurology and stroke center, Paris
Collaborators (2)
Pfizer
INDUSTRY
AstraZeneca
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Assistance Publique - Hôpitaux de Paris
OTHER